Market Overview:
The global hemophilia treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of hemophilia, rising awareness about hemophilia treatments, and technological advancements in the field of gene therapy. Hemophilia is a rare bleeding disorder caused by lack or deficiency of clotting factors in the blood, which leads to uncontrolled bleeding. There are three types of hemophilia: A (the most common), B, and von Willebrand disease (vWD). Hemophiliacs require regular injections of clotting factors to prevent or stop bleeding episodes. The major applications for hemoplia treatment are replacement therapy, ITI therapy, and gene therapy.
Product Definition:
Hemophilia Treatment is the medical term for the care and management of people who have hemophilia, a bleeding disorder. Hemophilia Treatment includes both preventive measures and treatment of bleeds.
On-demand:
On-demand (OD) is a new term in the hemophilia treatment market. It's basically an infusion therapy that allows patients to receive their regular clotting factor concentrates without having to go through the rigmarole of regular infusions. The major advantage of on-demand therapies is that they allow patients to administer medications as per their convenience, thereby reducing anxiety and improving quality of life.
The growth factor for on demand therapy is patient preference.
prophylaxis:
Prophylaxis is the practice of preventing disease by administering drugs or performing surgeries. In hemophilia treatment, prophylaxis refers to the practice of giving regular infusions of clotting factor concentrates to patients suffering from severe hemophilia. Prophylaxis helps in minimizing bleeding episodes and reduces the risk associated with them, thereby improving quality of life for affected individuals.
Application Insights:
The global market is segmented by application into replacement therapy, intrathecal therapy, interventional pain management and immunotherapy. Replacement therapies held the largest share in terms of revenue in 2017 owing to its high success rate and ability to prevent hemophilia from recurring. The introduction of recombinant factor VIII (Rixubis) and activated Factor VIII (Kinevac), which are manufactured using cell-based biopharmaceuticals technology has led to a significant increase in demand for replacement therapies worldwide.
On the other hand, interventional pain management held a considerable share due to an increase in number of patients opting for this type of treatment over others as it offers effective results with lesser side effects compared to other treatments such as radiofrequency ablation or spinal injections. Moreover, increasing cases of chronic pain coupled with rising geriatric population across the globe is expected fuel demand over the forecast period.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of regulatory authorities such as EMEA, FDA and WHO that approve and monitor the products used for treatment is one of the major factors contributing to its largest share. Moreover, high awareness levels about this condition among people and their willingness to spend more on healthcare are also driving growth.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to rising disposable income coupled with growing population especially in India & China. Rising prevalence of bleeding disorders due to modernization has led governments across countries including India & China as well as other developed nations such as U.S., UK, Germany etc.,to introduce policies related blood disorders which will boost market growth further over next eight years till 2030 time frame).
Growth Factors:
- Increasing incidence of hemophilia
- Growing demand for better and more effective hemophilia treatments
- Advances in gene therapy and other novel treatment approaches
- Increased focus on prophylaxis to prevent bleeds and improve outcomes
- Emerging markets offer significant growth potential
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophilia Treatment Market Research Report
By Type
On-demand, prophylaxis
By Application
Replacement therapy, ITI therapy, Gene therapy
By Companies
CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, Biogen, Novo Nordisk, Roche, Shire Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Hemophilia Treatment Market Report Segments:
The global Hemophilia Treatment market is segmented on the basis of:
Types
On-demand, prophylaxis
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Replacement therapy, ITI therapy, Gene therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- Baxalta
- Pfizer Inc
- BioMarin
- Bayer Healthcare
- Biogen
- Novo Nordisk
- Roche
- Shire Plc
Highlights of The Hemophilia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- On-demand
- prophylaxis
- By Application:
- Replacement therapy
- ITI therapy
- Gene therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophilia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophilia treatment is a combination of medications and regular blood transfusions to help manage the bleeding disorder. Treatment options may include:nnMedications : These medications can help control the amount of bleeding by stopping or slowing the production of blood clots. Some common types of hemophilia medication are warfarin (Coumadin) and inhibitors such as apixaban (Eliquis).nn: These medications can help control the amount of bleeding by stopping or slowing the production of blood clots. Some common types of hemophilia medication are warfarin (Coumadin) and inhibitors such as apixaban (Eliquis). Regular transfusions : A regular transfusion helps replace lost red blood cells, which helps prevent serious health complications from occurring due to low oxygen levels in your body. Hemophiliacs who require frequent transfusions typically receive them through a vein rather than an artery, which reduces potential risks associated with surgery.
Some of the major players in the hemophilia treatment market are CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, Biogen, Novo Nordisk, Roche, Shire Plc.
The hemophilia treatment market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemophilia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemophilia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemophilia Treatment Market - Supply Chain
4.5. Global Hemophilia Treatment Market Forecast
4.5.1. Hemophilia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemophilia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemophilia Treatment Market Absolute $ Opportunity
5. Global Hemophilia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemophilia Treatment Market Size and Volume Forecast by Type
5.3.1. On-demand
5.3.2. prophylaxis
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemophilia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemophilia Treatment Market Size and Volume Forecast by Application
6.3.1. Replacement therapy
6.3.2. ITI therapy
6.3.3. Gene therapy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemophilia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemophilia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemophilia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemophilia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemophilia Treatment Demand Share Forecast, 2019-2026
9. North America Hemophilia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemophilia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemophilia Treatment Market Size and Volume Forecast by Application
9.4.1. Replacement therapy
9.4.2. ITI therapy
9.4.3. Gene therapy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemophilia Treatment Market Size and Volume Forecast by Type
9.7.1. On-demand
9.7.2. prophylaxis
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemophilia Treatment Demand Share Forecast, 2019-2026
10. Latin America Hemophilia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemophilia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemophilia Treatment Market Size and Volume Forecast by Application
10.4.1. Replacement therapy
10.4.2. ITI therapy
10.4.3. Gene therapy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemophilia Treatment Market Size and Volume Forecast by Type
10.7.1. On-demand
10.7.2. prophylaxis
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemophilia Treatment Demand Share Forecast, 2019-2026
11. Europe Hemophilia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemophilia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemophilia Treatment Market Size and Volume Forecast by Application
11.4.1. Replacement therapy
11.4.2. ITI therapy
11.4.3. Gene therapy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemophilia Treatment Market Size and Volume Forecast by Type
11.7.1. On-demand
11.7.2. prophylaxis
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemophilia Treatment Demand Share, 2019-2026
12. Asia Pacific Hemophilia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemophilia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemophilia Treatment Market Size and Volume Forecast by Application
12.4.1. Replacement therapy
12.4.2. ITI therapy
12.4.3. Gene therapy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemophilia Treatment Market Size and Volume Forecast by Type
12.7.1. On-demand
12.7.2. prophylaxis
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemophilia Treatment Demand Share, 2019-2026
13. Middle East & Africa Hemophilia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemophilia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemophilia Treatment Market Size and Volume Forecast by Application
13.4.1. Replacement therapy
13.4.2. ITI therapy
13.4.3. Gene therapy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemophilia Treatment Market Size and Volume Forecast by Type
13.7.1. On-demand
13.7.2. prophylaxis
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemophilia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemophilia Treatment Market: Market Share Analysis
14.2. Hemophilia Treatment Distributors and Customers
14.3. Hemophilia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. CSL Behring
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Baxalta
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BioMarin
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer Healthcare
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biogen
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novo Nordisk
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shire Plc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
